Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 7, 2015, Pages 756-764

  Falanga, Anna ^a   Schieppati, Francesca ^b   Russo, Domenico ^b  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

cancer; risk factors; thrombosis; tissue factor; tumor cells

Indexed keywords

CANCER PROCOAGULANT; THROMBOPLASTIN; TUMOR PROTEIN;

ARTICLE; BLOOD CLOTTING; CANCER CELL; CANCER PATIENT; HUMAN; HYPERCOAGULABILITY; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; THROMBOSIS; BIOSYNTHESIS; BLOOD; GENE EXPRESSION REGULATION; MORTALITY; NEOPLASMS; PATHOLOGY; THROMBOPHILIA;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; THROMBOPHILIA; THROMBOPLASTIN; THROMBOSIS;

EID: 84943610050     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1564040     Document Type: Article

References (78)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel Dieu de Paris: 1856; Vol. 3 654 712
2. Falanga A., Marchetti M., Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost: 2013; 11 2 223 233
3. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost: 2005; 31 1 104 110
4. Falanga A., Panova-Noeva M., Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol: 2009; 22 1 49 60
5. Zwicker J. I., Liebman H. A., Bauer K. A., et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol: 2013; 160 4 530 537
6. Khorana A. A., McCrae K. R. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res: 2014; 133 02 S35 S38
7. Hamada K., Kuratsu J., Saitoh Y., Takeshima H., Nishi T., Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer: 1996; 77 9 1877 1883
8. Takano S., Tsuboi K., Tomono Y., Mitsui Y., Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer: 2000; 82 12 1967 1973
9. Guan M., Jin J., Su B., Liu W. W., Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem: 2002; 35 4 321 325
10. Ishimaru K., Hirano H., Yamahata H., Takeshima H., Niiro M., Kuratsu J. The expression of tissue factor correlates with proliferative ability in meningioma. Oncol Rep: 2003; 10 5 1133 1137
11. Fernandes R. S., Kirszberg C., Rumjanek V. M., Monteiro R. Q. On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J Thromb Haemost: 2006; 4 7 1546 1552
12. Nadir Y., Brenner B. Heparanase multiple effects in cancer. Thromb Res: 2014; 133 02 S90 S94
13. Elkin M., Ilan N., Ishai-Michaeli R., et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J: 2001; 15 9 1661 1663
14. Fux L., Feibish N., Cohen-Kaplan V., et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res: 2009; 69 5 1758 1767
15. Falanga A., Consonni R., Marchetti M., et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood: 1998; 92 1 143 151
16. Falanga A., Iacoviello L., Evangelista V., et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood: 1995; 86 3 1072 1081
17. Falanga A., Toma S., Marchetti M., et al. Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer. Am J Hematol: 2002; 70 1 9 15
18. Ahn Y. S. Cell-derived microparticles: 'Miniature envoys with many faces' J Thromb Haemost: 2005; 3 5 884 887
19. Horstman L. L., Jy W., Jimenez J. J., Bidot C., Ahn Y. S. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med: 2004; 53 4 210 230
20. Falanga A., Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol: 2009; 27 29 4848 4857
21. Kim H. K., Song K. S., Park Y. S., et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer: 2003; 39 2 184 191
22. Del Conde I., Bharwani L. D., Dietzen D. J., Pendurthi U., Thiagarajan P., López J. A. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost: 2007; 5 1 70 74
23. Tilley R. E., Holscher T., Belani R., Nieva J., Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res: 2008; 122 5 604 609
24. Garnier D., Magnus N., Lee T. H., et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem: 2012; 287 52 43565 43572
25. Davila M., Amirkhosravi A., Coll E., et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost: 2008; 6 9 1517 1524
26. Manly D. A., Wang J., Glover S. L., et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res: 2010; 125 6 511 512
27. Kwaan H. C., Rego E. M. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost: 2010; 36 8 917 924
28. Van Aalderen M. C., Trappenburg M. C., Van Schilfgaarde M., et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost: 2011; 9 1 223 226
29. Auwerda J. J., Yuana Y., Osanto S., et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost: 2011; 105 1 14 20
30. Trappenburg M. C., van Schilfgaarde M., Marchetti M., et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica: 2009; 94 7 911 918
31. Liu Y., Wang Z., Jiang M., et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res: 2011; 35 7 879 884
32. van Hinsbergh V. W., Bauer K. A., Kooistra T., et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood: 1990; 76 11 2284 2289
33. Van de Wouwer M., Collen D., Conway E. M. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol: 2004; 24 8 1374 1383
34. Rickles F. R., Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res: 2001; 102 6 V215 V224
35. Falanga A., Marchetti M., Vignoli A., Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol: 2003; 1 11 673 678
36. Demers M., Wagner D. D. Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. OncoImmunology: 2013; 2 2 e22946
37. Demers M., Krause D. S., Schatzberg D., et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A: 2012; 109 32 13076 13081
38. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science: 2004; 303 5663 1532 1535
39. Fuchs T. A., Brill A., Duerschmied D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A: 2010; 107 36 15880 15885
40. Massberg S., Grahl L., von Bruehl M. L., et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med: 2010; 16 8 887 896
41. Snyder K. M., Kessler C. M. The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost: 2008; 34 8 734 741
42. Bastida E., Ordinas A., Giardina S. L., Jamieson G. A. Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res: 1982; 42 11 4348 4352
43. Pinto S., Gori L., Gallo O., Boccuzzi S., Paniccia R., Abbate R. Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids: 1993; 49 1 527 530
44. Zucchella M., Dezza L., Pacchiarini L., et al. Human tumor cells cultured in vitro activate platelet function by producing ADP or thrombin. Haematologica: 1989; 74 6 541 545
45. Grignani G., Pacchiarini L., Ricetti M. M., et al. Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metastasis: 1989; 9 5 298 309
46. Gasic G. J., Gasic T. B., Stewart C. C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A: 1968; 61 1 46 52
47. Stegner D., Dütting S., Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res: 2014; 133 02 S149 S157
48. Honn K. V., Tang D. G., Crissman J. D. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev: 1992; 11 3-4 325 351
49. Karpatkin S., Pearlstein E., Ambrogio C., Coller B. S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest: 1988; 81 4 1012 1019
50. Palumbo J. S., Talmage K. E., Massari J. V., et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood: 2005; 105 1 178 185
51. Nieswandt B., Hafner M., Echtenacher B., Männel D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res: 1999; 59 6 1295 1300
52. Shau H., Roth M. D., Golub S. H. Regulation of natural killer function by nonlymphoid cells. Nat Immun: 1993; 12 4-5 235 249
53. Placke T., Örgel M., Schaller M., et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res: 2012; 72 2 440 448
54. Möhle R., Green D., Moore M. A., Nachman R. L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A: 1997; 94 2 663 668
55. Yang L., Carbone D. P. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res: 2004; 92 13 27
56. Tímár J., Tóvári J., Rásó E., Mészáros L., Bereczky B., Lapis K. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology: 2005; 69 3 185 201
57. Rice G. E., Bevilacqua M. P. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science: 1989; 246 4935 1303 1306
58. Giavazzi R., Foppolo M., Dossi R., Remuzzi A. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. J Clin Invest: 1993; 92 6 3038 3044
59. Chen M., Geng J. G. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz): 2006; 54 2 75 84
60. Coppinger J. A., Cagney G., Toomey S., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood: 2004; 103 6 2096 2104
61. David M., Wannecq E., Descotes F., et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE: 2010; 5 3 e9741
62. Reed G. L. Platelet secretory mechanisms. Semin Thromb Hemost: 2004; 30 4 441 450
63. Ren Q., Ye S., Whiteheart S. W. The platelet release reaction: just when you thought platelet secretion was simple. Curr Opin Hematol: 2008; 15 5 537 541
64. Bendas G., Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol: 2012; 2012 676731
65. Nomura S., Suzuki M., Katsura K., et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis: 1995; 116 2 235 240
66. Mallat Z., Benamer H., Hugel B., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation: 2000; 101 8 841 843
67. Nieuwland R., Berckmans R. J., McGregor S., et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood: 2000; 95 3 930 935
68. Chirinos J. A., Heresi G. A., Velasquez H., et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol: 2005; 45 9 1467 1471
69. Weitz I. C., Israel V. K., Waisman J. R., Presant C. A., Rochanda L., Liebman H. A. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost: 2002; 88 2 213 220
70. Khorana A. A., Francis C. W., Culakova E., Lyman G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer: 2005; 104 12 2822 2829
71. Ay C., Simanek R., Vormittag R., et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood: 2008; 112 7 2703 2708
72. Ay C., Vormittag R., Dunkler D., et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol: 2009; 27 25 4124 4129
73. Khorana A. A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood: 2008; 111 10 4902 4907
74. Ay C., Dunkler D., Marosi C., et al. Prediction of venous thromboembolism in cancer patients. Blood: 2010; 116 24 5377 5382
75. Moore R. A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol: 2011; 29 25 3466 3473
76. Mandala M., Clerici M., Corradino I., et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience' Ann Oncol: 2012; 23 6 1416 1421
77. Verso M., Agnelli G., Barni S., Gasparini G., LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med: 2012; 7 3 291 292
78. Palumbo A., Rajkumar S. V., Dimopoulos M. A., et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia: 2008; 22 2 414 423